Treatment with 10 mg of tirzepatide reduced NASH-related biomarkers, such as serum ALT and aspartate aminotransferase (AST), in patients with T2DM (NCT03131687)338. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.